The Duke Funding Alert newsletter, published every Monday, provides information on all new and updated grants and fellowships added to the database during the prior week. This listserv is restricted to members of the Duke community.
Congressionally Directed Medical Research Programs (CDMRP) -- Bone Marrow Failure Research Program -- Investigator-Initiated Research Award
The FY22 BMFRP IIRA will offer two funding levels with different intent:
Funding Level 1 (FL1): To support studies that further develop ideas, expand upon key discoveries, and have the potential to make significant advances in research, patient care, and/or quality of life in the FY22 BMFRP IIRA Focus Areas. IIRA applications may involve basic, translational, and clinically oriented research, including studies in animal models, research with human anatomical substances, and research with human subjects, as well as correlative studies associated with an existing clinical trial; however, FL1 awards may not be used to support a clinical trial. Multidisciplinary collaborations are encouraged.
Funding Level 2 (FL2): To support Investigational New Drug (IND)-enabling efforts. The BMFRP recognizes the scientific and financial challenges associated with advancing promising, potentially life-changing, therapeutic agents from the laboratory to clinical evaluation. Data related to lead compound characterization; formulation and stability; absorption, distribution, metabolism and excretion; dose/response; and toxicology are required before clinical trials can commence. The proposed studies under the FL2 IND-enabling efforts are expected to be empirical in nature, product-driven, and focused on the accumulation of data for a lead therapeutic candidate(s). At least one, and no more than three, lead therapeutic candidates must be named at the time of application submission to meet the intent of the FL2 mechanism. Library screening or drug optimization studies do not meet the intent of FL2. At the end of the period of performance, the cumulative data should be sufficient to submit an IND to the Food and Drug Administration (FDA). The intent of FL2 awards is to perform the necessary evaluation of promising therapies that will lead to clinical trials; however, clinical trials themselves are not supported by this mechanism. FL2 applications must address the FY22 BMFRP Focus Area “Find effective BMF treatments and cures”.
- Pre-Application Deadline: June 29, 2022
- Invitation to Submit an Application: August 2022
- Application Submission Deadline: Sep. 23, 2022
Areas of Interest
To meet the intent of the award mechanism, applications must address at least one of the FY22 BMFRP Investigator-Initiated Research Award (IIRA) Focus Areas listed below. Selection of the appropriate Focus Area is the responsibility of the applicant.
• Understand the causes and progression of BMF diseases
• Find effective BMF treatments and cures
Investigators at or above the level of Assistant Professor (or equivalent) may be named by the applicant organization as the PI or Partnering PI on the application. An eligible PI, regardless of ethnicity, nationality, or citizenship status, must be employed by, or affiliated with, an eligible organization.
The anticipated direct [costs budgeted for the entire period of performance for an FY22 BMFRP IIRA FL1Award will not exceed $600,000 and the anticipated direct cost budgeted for the entire period of performance for an FY22 BMFRP IIRA FL2 award will not exceed $800,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.